PriceTargets.com logo

Hoth Therapeutics - HOTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $66.50
  • Forecasted Upside: 3,208.46%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.01 As of 03/24/2023 01:00 AM ET
▲ +0.05 (2.55%)

This chart shows the closing price for HOTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hoth Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOTH

Analyst Price Target is $66.50
▲ +3,208.46% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Hoth Therapeutics in the last 3 months. The average price target is $66.50, with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 3,208.46% upside from the last price of $2.01.

This chart shows the closing price for HOTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Hoth Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/30/2022EF Hutton Acquisition Co. ILower TargetBuy$45.00 ➝ $33.00N/A
5/27/2022BenchmarkLower Target$100.00Low
10/15/2019BenchmarkInitiated CoverageSpeculative Buy$250.00High
5/20/2019LaidlawInitiated CoverageBuy$250.00Low
(Data available from 3/26/2018 forward)

News Sentiment Rating

-1.26 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
1/25/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Hoth Therapeutics logo
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Read More

Today's Range

Now: $2.01
Low: $1.97
High: $2.06

50 Day Range

MA: $3.51
Low: $1.96
High: $6.43

52 Week Range

Now: $2.01
Low: $1.93
High: $40.74

Volume

25,644 shs

Average Volume

262,477 shs

Market Capitalization

$2.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Hoth Therapeutics?

The following Wall Street analysts have issued reports on Hoth Therapeutics in the last year: Benchmark Co., and EF Hutton Acquisition Co. I.
View the latest analyst ratings for HOTH.

What is the current price target for Hoth Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Hoth Therapeutics in the last year. Their average twelve-month price target is $66.50, suggesting a possible upside of 3,208.5%. Benchmark Co. has the highest price target set, predicting HOTH will reach $100.00 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $33.00 for Hoth Therapeutics in the next year.
View the latest price targets for HOTH.

What is the current consensus analyst rating for Hoth Therapeutics?

Hoth Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOTH will outperform the market and that investors should add to their positions of Hoth Therapeutics.
View the latest ratings for HOTH.

What other companies compete with Hoth Therapeutics?

Other companies that are similar to Hoth Therapeutics include Petros Pharmaceuticals, NovaBay Pharmaceuticals, First Wave BioPharma, Allarity Therapeutics and Bellicum Pharmaceuticals. Learn More about companies similar to Hoth Therapeutics.

How do I contact Hoth Therapeutics' investor relations team?

Hoth Therapeutics' physical mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company's listed phone number is (646) 756-2997 and its investor relations email address is [email protected] The official website for Hoth Therapeutics is www.hoththerapeutics.com. Learn More about contacing Hoth Therapeutics investor relations.